Bioverativ (BIVV) Getting Somewhat Favorable Press Coverage, Analysis Finds

Media stories about Bioverativ (NASDAQ:BIVV) have trended somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioverativ earned a news impact score of 0.11 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.2265638138837 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news articles that may have impacted Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

BIVV stock traded up $0.33 during mid-day trading on Thursday, reaching $104.98. The company’s stock had a trading volume of 792,900 shares, compared to its average volume of 3,027,685. Bioverativ has a fifty-two week low of $48.14 and a fifty-two week high of $105.01.

Bioverativ (NASDAQ:BIVV) last announced its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.01. The business had revenue of $328.70 million during the quarter, compared to the consensus estimate of $325.89 million. Bioverativ had a net margin of 30.43% and a return on equity of 40.99%. sell-side analysts expect that Bioverativ will post 3.82 earnings per share for the current year.

A number of research firms have commented on BIVV. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price objective for the company in a report on Monday, January 8th. William Blair reiterated a “hold” rating on shares of Bioverativ in a report on Thursday, March 8th. Royal Bank of Canada increased their price objective on shares of Bioverativ to $68.00 and gave the company a “market perform” rating in a report on Thursday, January 18th. Jefferies Group increased their price objective on shares of Bioverativ to $79.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Finally, Raymond James downgraded shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Twelve analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of $64.70.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at

Bioverativ Company Profile

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Insider Buying and Selling by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with's FREE daily email newsletter.

Leave a Reply